Medivation Announces Participation at Two Upcoming Investor Conferences
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 09/06/11 -- Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will participate at the following two investor conferences:
Panel discussion titled "Finally Lots of Options in Treating Prostate Cancer" at Citi's 6th Annual Biotech Day on Wednesday, September 7 at 11 a.m. Eastern Time at the Ritz Carlton Boston Commons in Boston, MA
Company overview at the UBS Global Life Sciences Conference on Wednesday, September 21 at 10 a.m. Eastern Time at the Grand Hyatt Hotel in New York, NY
A live audio webcast of the company overview will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at . A replay also will be available for 30 days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at .
Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
Anne Bowdidge
Investor Relations
(650) 218-6900
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.09.2011 - 05:01 Uhr
Sprache: Deutsch
News-ID 1036896
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 127 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medivation Announces Participation at Two Upcoming Investor Conferences
"
steht unter der journalistisch-redaktionellen Verantwortung von
Medivation, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
